| UniProt/SwissProt ID: | TEBP_HUMAN |
| Description: | prostaglandin E synthase 3 (cytosolic) [Source:HGNC Symbol;Acc:16049] |
| Location: | chr12 q13.3 |
| Node attribute: | substrate |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| S85 | GESGQsWPRLT | PhosphoSitePlus; HPRD | |
| S113 | DWEDDsDEDMS | Pkinase_C | PhosphoSitePlus; SysPTM |
| S113 | DWEDDsDEDMS | HPRD; phosphoELM; RegPhos; SysPTM | |
| S118 | SDEDMsNFDRF | CK2a1(CK2 alpha | RegPhos; SysPTM |
| S124 | NFDRFsEMMNN | HPRD | |
| S148 | GADDDsQDSDD | Pkinase_C | PhosphoSitePlus; SysPTM |
| S124 | NFDRFsEMMNN | Pkinase_C | PhosphoSitePlus |
| S118 | SDEDMsNFDRF | CK2_alpha | phosphoELM; SysPTM |
| S148 | GADDDsQDSDD | HPRD; phosphoELM; RegPhos; SysPTM | |
| S151 | DDSQDsDDEKM | Pkinase_C | PhosphoSitePlus; SysPTM |
| S118 | SDEDMsNFDRF | Pkinase_C | PhosphoSitePlus; SysPTM |
| S100 | KLNWLsVDFNN | HPRD | |
| S151 | DDSQDsDDEKM | HPRD; phosphoELM; RegPhos; SysPTM | |
| S113 | DWEDDsDEDMS | CK2_alpha | phosphoELM; SysPTM |
| Y14 | YDRRDyVFIEF | CS | PhosphoSitePlus |
| S118 | SDEDMsNFDRF | HPRD; phosphoELM; RegPhos; SysPTM | |
| S113 | DWEDDsDEDMS | CK2a1(CK2 alpha | RegPhos; SysPTM |
| Dephosphorylation site |
| TEBP_HUMAN do not have dephosphorylation site. |
| Mutation site |
| Ensembl ID | Variation | Source | Cancer name | Pubmed |
|---|---|---|---|---|
| ENSP00000262033 | H66P | BIOMART | Pancreatic Cancer | 21930507, 21930502 |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000262033 | Prostate Cancer | Metastasis | cell line | Down | 0.14 | 15102926 | ENSP00000262033 | Prostate Cancer | Metastasis | tissue | Up | 3.1 | 18553995 | ENSP00000262033 | Hepatocellular Carcinoma | Treatment (none vs. Suberonylanilide hydroxamic acid (SAHA) treatment) | tissue | Down | 17593366 | ENSP00000262033 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.6 | 20052998 | ENSP00000262033 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.2 | 20052998 | ENSP00000262033 | Breast Cancer | Metastasis | cell line | Down | 0.72 | 20052998 | ENSP00000262033 | Neoplasms by Histologic Type | Treatment (none vs. SB203580 treatment 21 hour) | cell line | Up | 1.8 | 15169874 | ENSP00000262033 | Uterine Cancer | Treatment (none vs. Suberonylanilide hydroxamic acid (SAHA) treatment) | cell line | Up | 19179759 |
| Hyperphosphorylation site |
| TEBP_HUMAN do not have hyperphosphorylation site. |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| ZAGL2_HUMAN | TEBP_HUMAN | kinase -> substrate | RegPhos |
| CSK21_HUMAN | TEBP_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| Function Annotation |
| KEGG Pathway |
| KEGG ID | Pathway |
|---|---|
| hsa01100 | Metabolic pathways |
| hsa00590 | Arachidonic acid metabolism |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0070389 | chaperone cofactor-dependent protein refolding | IDA | biological_process |
| GO:0051082 | unfolded protein binding | IDA | molecular_function |
| GO:0005829 | cytosol | TAS | cellular_component |
| GO:0005737 | cytoplasm | IDA | cellular_component |
| GO:0005634 | nucleus | IDA | cellular_component |
| GO:0000723 | telomere maintenance | TAS | biological_process |
| GO:0001516 | prostaglandin biosynthetic process | IEA | biological_process |
| GO:0050220 | prostaglandin-E synthase activity | IDA | molecular_function |
| GO:0005697 | telomerase holoenzyme complex | IDA | cellular_component |
| GO:0000781 | chromosome, telomeric region | IC | cellular_component |
| GO:0007165 | signal transduction | TAS | biological_process |
| GO:0003720 | telomerase activity | IDA | molecular_function |
| GO:0005515 | protein binding | IPI | molecular_function |